Compare T Rowe Price Group Inc (TROW) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
T Rowe Price Group Inc vs GeneDx Holdings Corp — how do they compare? T Rowe Price Group Inc trades at $113.73 (market cap $23.77B), while GeneDx Holdings Corp trades at $82.2 (market cap $2.45B). The key difference: T Rowe Price Group Inc is far larger — about 9.7× GeneDx Holdings Corp's market cap, and T Rowe Price Group Inc pays a 4.67% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| TROW | WGS | |
|---|---|---|
Market Cap | $23.77B | $2.45B |
Sector | Financials | Technology |
52-Week High | $121.68 | $167.51 |
52-Week Low | $86.19 | $34.51 |
Enterprise Value | $20.96B | $2.49B |
Dividend Yield | 4.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
T. Rowe Price (TROW) trades at $111.49, down 2.0% on the day, with a bearish technical signal from moving averages. The stock shows solid fundamentals with a P/E of 11.42, net income margin of 29.26%, and consistent dividend payments of $1.30 per share. Recent Q2 2026 earnings beat expectations with EPS of $2.57 versus $2.51 estimated, driven by higher assets under management and advisory revenue.
The outlook is mixed: strong profitability and a consensus price target of $112.17 offer upside, but bearish technicals and expense pressures pose risks. Investor sentiment is cautious with 63% analyst hold ratings, reflecting concerns over net outflows and market volatility impacting asset management fees.
GeneDx Holdings Corp (WGS) trades at $82.39, up 5.79% in the past 24 hours, with a bullish technical signal and strong analyst support. The company reported Q2 2026 revenue of $114.4 million, beating guidance, and returned to adjusted profitability earlier than expected. However, net income remains negative at -$106 million for 2026, and the stock faces class action lawsuits with an August 3, 2026 deadline.
Outlook is mixed: bullish technicals and analyst consensus suggest upside to the $90 price target, but fundamental weaknesses and legal risks pose significant challenges. Investment opportunity hinges on sustained revenue growth and margin improvement, while risks include profitability pressures and litigation outcomes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
